# Glycomine

> Glycomine is a San Carlos clinical-stage biotechnology company developing GLM101, a weekly intravenous liposomal mannose-1-phosphate replacement therapy for PMM2-CDG. Its premise is to bypass a defective enzyme and restore a disrupted glycosylation pathway. A 43-participant randomized Phase 2b trial has completed enrollment; no product is approved.

- **Founded:** 2014
- **Headquarters:** San Carlos, United States
- **Products:** GLM101, Replacement therapy platform
- **Notable:** Reported an average 11.9-point ICARS improvement after 24 weeks in nine adolescent and adult participants in an open-label Phase 2 analysis; controlled confirmation is pending., Completed POLAR Phase 2b enrollment in April 2026: 43 participants across 15 sites., Received U.S. and EU Orphan Drug designations and U.S. Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations.

## Products & services

- **GLM101** — Investigational liposomal mannose-1-phosphate substrate replacement therapy for PMM2-CDG; administered by weekly IV infusion and evaluated in the POLAR Phase 2b trial.
- **Replacement therapy platform** — Research approach for delivering substrates, enzymes, or proteins to clinically relevant cells and organ systems; no other named clinical product confirmed.

## Achievements

- Reported an average 11.9-point ICARS improvement after 24 weeks in nine adolescent and adult participants in an open-label Phase 2 analysis; controlled confirmation is pending.
- Completed POLAR Phase 2b enrollment in April 2026: 43 participants across 15 sites.
- Received U.S. and EU Orphan Drug designations and U.S. Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations.
- Raised $195 million in announced Series A, B and C financing.

## Latest updates

- **2026-09** — FDA granted GLM101 Breakthrough Therapy designation based on open-label Phase 2a evidence; randomized POLAR topline results expected in Q4 2026.
- **2026-04** — POLAR completed enrollment of 43 patients across 15 sites.
- **2025-09** — First participant dosed in the randomized POLAR Phase 2b study.
- **2025-04** — Raised $115 million Series C to support POLAR.

## Links

- Website: https://www.glycomine.com/
- LinkedIn: https://www.linkedin.com/company/glycomine-inc-
- Twitter/X: https://twitter.com/GlycomineBio

---

Profile page: https://yespress.io/glycomine
Published by YesPress — https://yespress.io
Last updated: 2026-09-29